全文获取类型
收费全文 | 3713篇 |
免费 | 315篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 84篇 |
妇产科学 | 30篇 |
基础医学 | 853篇 |
口腔科学 | 25篇 |
临床医学 | 186篇 |
内科学 | 637篇 |
皮肤病学 | 70篇 |
神经病学 | 504篇 |
特种医学 | 180篇 |
外科学 | 231篇 |
综合类 | 343篇 |
预防医学 | 173篇 |
眼科学 | 35篇 |
药学 | 423篇 |
3篇 | |
中国医学 | 78篇 |
肿瘤学 | 256篇 |
出版年
2023年 | 37篇 |
2022年 | 68篇 |
2021年 | 114篇 |
2020年 | 103篇 |
2019年 | 88篇 |
2018年 | 110篇 |
2017年 | 121篇 |
2016年 | 114篇 |
2015年 | 134篇 |
2014年 | 230篇 |
2013年 | 267篇 |
2012年 | 170篇 |
2011年 | 214篇 |
2010年 | 146篇 |
2009年 | 153篇 |
2008年 | 175篇 |
2007年 | 176篇 |
2006年 | 157篇 |
2005年 | 147篇 |
2004年 | 122篇 |
2003年 | 157篇 |
2002年 | 99篇 |
2001年 | 82篇 |
2000年 | 96篇 |
1999年 | 75篇 |
1998年 | 49篇 |
1997年 | 48篇 |
1996年 | 64篇 |
1995年 | 57篇 |
1994年 | 58篇 |
1993年 | 45篇 |
1992年 | 45篇 |
1991年 | 45篇 |
1990年 | 38篇 |
1989年 | 39篇 |
1988年 | 26篇 |
1987年 | 22篇 |
1986年 | 24篇 |
1985年 | 37篇 |
1984年 | 28篇 |
1983年 | 14篇 |
1982年 | 24篇 |
1981年 | 21篇 |
1980年 | 14篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1977年 | 10篇 |
1976年 | 10篇 |
1974年 | 6篇 |
1973年 | 7篇 |
排序方式: 共有4132条查询结果,搜索用时 15 毫秒
1.
2.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
3.
4.
Yeon Seok Lee June Hyunkyung Lee Jae Eun Choi Joo Young Kim Tae Young Han 《Pediatric dermatology》2021,38(1):290-291
Erythema induratum of Bazin (EIB) is a form of tuberculid resulting from hypersensitivity to tuberculosis antigen. EIB occurs most commonly in middle‐aged women and is not typically seen in children. Here, we present a rare case of EIB, presenting as a chronic nodular panniculitis, in a 10‐year‐old Korean boy. 相似文献
5.
Thomas Asendorf Robin Henderson Heinz Schmidli Tim Friede 《Statistics in medicine》2019,38(9):1503-1528
In some diseases, such as multiple sclerosis, lesion counts obtained from magnetic resonance imaging (MRI) are used as markers of disease progression. This leads to longitudinal, and typically overdispersed, count data outcomes in clinical trials. Models for such data invariably include a number of nuisance parameters, which can be difficult to specify at the planning stage, leading to considerable uncertainty in sample size specification. Consequently, blinded sample size re-estimation procedures are used, allowing for an adjustment of the sample size within an ongoing trial by estimating relevant nuisance parameters at an interim point, without compromising trial integrity. To date, the methods available for re-estimation have required an assumption that the mean count is time-constant within patients. We propose a new modeling approach that maintains the advantages of established procedures but allows for general underlying and treatment-specific time trends in the mean response. A simulation study is conducted to assess the effectiveness of blinded sample size re-estimation methods over fixed designs. Sample sizes attained through blinded sample size re-estimation procedures are shown to maintain the desired study power without inflating the Type I error rate and the procedure is demonstrated on MRI data from a recent study in multiple sclerosis. 相似文献
6.
7.
8.
9.
为探讨曲格列酮(troglitazone,TGZ)对人卵巢颗粒细胞芳香化酶(P450arom)活性的调节作用,以不同剂量的TGZ和(或)维甲酸类X受体(RXR)激动剂(LG100268,LG)处理来源于体外受精患者的卵巢颗粒细胞24h,然后测定细胞的芳香化酶活性和P450arom mRNA水平。结果发现,TGZ处理颗粒细胞24h可引起剂量依赖性的芳香化酶活性下降;LG单独作用可以抑制芳香化酶活性,但与TGZ合用对芳香化酶的抑制作用更明显;RT-PCR结果显示,随着芳香化酶活性的下降,P450arom mRNA表达水平也降低。表明TGZ可能是通过过氧化物酶体增殖物激活受体γ(PPARγ):RXR异二聚体组成的核受体系统直接抑制卵巢颗粒细胞芳香化酶活性。 相似文献
10.
Jasper E Visser Bastiaan R Bloem Bart P C van de Warrenburg 《Movement disorders》2007,22(7):1024-1026
Progressive myoclonic ataxia, also referred to as Ramsay Hunt syndrome, is characterized by a combination of myoclonus and cerebellar ataxia, infrequently accompanied by tonic-clonic seizures. Its differential diagnosis overlaps with progressive myoclonic epilepsy, a syndrome with myoclonus, tonic-clonic seizures, progressive ataxia and dementia. In patients with progressive myoclonic epilepsy, specific diseases can frequently be recognized, but the diagnostic yield in progressive myoclonic ataxia is much lower. We describe a patient who presented with multifocal myoclonus in his thirties and who later developed cerebellar ataxia and focal dystonia. His father was similarly affected. Genetic studies revealed a mutation in the protein kinase C gamma (PRKCG) gene, known to cause spinocerebellar ataxia type 14 (SCA-14). This case illustrates that both myoclonus and dystonia are part of the clinical spectrum in SCA-14 and that myoclonus can even be the presenting symptom. We suggest that SCA-14 should be considered in the differential diagnosis of progressive myoclonic ataxia. 相似文献